Straumann net revenue up to CHF554.1m in Jan-Sep 2010.
M2 PHARMA-October 29, 2010-Straumann net revenue up to CHF554.1m in Jan-Sep 2010(C)2010 M2 COMMUNICATIONS
29 October 2010 - Swiss implant and restorative dentistry and oral tissue regeneration company Straumann Holding AG (VTX: STMN) said yesterday that its net revenue grew to CHF554.1m (USD562.1m/EUR404.9m) for the first nine months of 2010 from CHF552.3m for the same period of 2009.
The company's revenue for the period under review was driven by an increase in the volume of implants sold, thanks mainly to the continued strong uptake of the Bone Level implant range. Additional impetus was provided by recently launched products like Roxolid and Straumann Allograft. However, the CADCAM business posted lower sales than in the comparative period last year as prospective customers were waiting for the launch of Straumann's new in-lab scanner and CADCAM system, which became available at the end of the third quarter. The CADCAM elements business continued to grow throughout the year.
Net revenue in Europe for the January-September 2010 period decreased to CHF334m from CHF345m for the same period a year earlier, corresponding to 60% of the company's total. North America posted another encouraging quarter, as nine-month net revenue rose to CHF123m from CHF117.1m, or 22% of the company's total. The Asia/Pacific region contributed 14%, or CHF76m, to net revenue in the first nine months. Net revenue in the Rest of the World region contributed 4% to the company's total and grew to CHF20m from CHF17.1m, driven by good performances in Brazil, Mexico and countries in the Middle East.
In the third quarter of 2010, Straumann's revenue decreased to CHF161.6m from CHF168.2m for the same period a year earlier.
Straumann expects to achieve levels of full-2010 net revenue and operating margin at least in line with the prior year, in spite of additional second-half operating expenses related to the introduction of new products/technologies in digitalisation and regeneratives.
(CHF1 = USD1.015/EUR0.731)
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 29, 2010|
|Previous Article:||Bristol-Myers Squibb, Otsuka say FDA OKs SPRYCEL as treatment for adult patients with newly diagnosed Ph+ CML in chronic phase.|
|Next Article:||Hikma to purchase Baxter's US generic injectables biz for USD112m.|